Argenx SE stock surges on robust 2025 annual report highlighting VYVGART growth and pipeline catalysts

Argenx SE (ISIN: NL0010832176) released its 2025 annual report, showcasing $4.2 billion in product net sales and over 19,000 VYVGART patients. The biotech leader advances 10 registrational trials amid a planned CEO transition, drawing investor focus on immunology innovation.

Argenx SE, the Netherlands-based biotech powerhouse, filed its 2025 annual report this week, revealing explosive growth for its flagship therapy VYVGART and a pipeline brimming with high-potential autoimmune treatments. Net product sales hit $4.2 billion, fueled by over 19,000 patients across generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP). This milestone underscores argenx's dominance in FcRn inhibition, with subcutaneous formulations expanding access and market share. For DACH investors, the report signals sustained revenue momentum in a sector ripe for M&A and partnerships, especially as European regulators fast-track approvals.

As of: 19.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – 'Argenx's Immunology Innovation Program positions it as a European biotech leader, with 2025 results validating long-term value creation in autoimmune therapies amid global demand surges.'

Record VYVGART Sales Drive 2025 Momentum

Argenx's lead product VYVGART achieved blockbuster status in 2025, generating $4.2 billion in net sales across intravenous and subcutaneous versions like VYVGART HYTRULO and VYVDURA. The therapy reached more than 19,000 patients globally in three key indications: gMG, CIDP, and ITP. In gMG, VYVGART solidified its position as the number one prescribed biologic, with uptake shifting to earlier treatment lines and broader patient segments.

Launches of pre-filled syringe (PFS) options enhanced patient convenience, boosting adherence and market penetration. Positive topline data from the seronegative gMG trial bolsters ambitions for the broadest myasthenia gravis label yet. These developments explain the market's enthusiasm, as VYVGART's expansion validates argenx's commercial execution in competitive autoimmune markets.

For DACH investors, VYVGART's European approvals and pricing power offer a hedge against U.S.-centric biotech volatility. Reimbursement pathways in Germany, Austria, and Switzerland are progressing, with gMG and CIDP listings supporting steady revenue inflows.

Pipeline Depth Signals Multi-Billion Dollar Future

Argenx enters 2026 with 10 ongoing registrational clinical trials, spanning efgartigimod (VYVGART's active), empasiprubart, and adimanebart. Key readouts loom in myositis (ALKIVIA trial, 3Q 2026), Sjögren’s disease (UNITY, 2H 2027), and ITP (ADVANCE-NXT, 4Q 2026). Empasiprubart, a first-in-class C2 complement inhibitor, advances in multifocal motor neuropathy (MMN) and CIDP Phase 3 studies, targeting unmet needs in neuromuscular diseases.

Four new molecules joined the pipeline in 2025, three now entering Phase 1, all rooted in the Immunology Innovation Program (IIP). Next-generation FcRn candidates like ARGX-213 and ARGX-124, plus autoinjector preparations for 2027, aim to extend dominance. Rheumatology expansions into autoimmune inflammatory myopathies and Sjögren’s could unlock additional blockbusters.

Markets care now because these catalysts cluster in 2026-2027, de-risking revenue beyond VYVGART. DACH portfolios benefit from argenx's EU headquarters, facilitating access to grants and regional trials.

CEO Transition: Continuity with Fresh Leadership

Tim Van Hauwermeiren plans to step down as CEO in 2026, transitioning to Non-Executive Chairperson pending shareholder approval at the May 6 AGM. COO Karen Massey is poised to succeed, bringing operational expertise from VYVGART's global launches. This orderly handover minimizes disruption, with Van Hauwermeiren's continued board role ensuring strategic continuity.

The market views this positively, as argenx's IIP and commercial engine are well-established. Heavy R&D investment in 2025 underscores commitment to innovation, balancing growth with pipeline advancement. Investors appreciate transparent succession in biotech, where leadership stability often correlates with execution.

DACH stakeholders should note argenx's Dutch base aligns with EU talent pools, potentially accelerating Massey's integration.

Why DACH Investors Should Prioritize Argenx Now

German-speaking investors hold a home-field advantage with argenx SE (ISIN NL0010832176), listed primarily on Euronext Brussels and NASDAQ in EUR and USD respectively. Europe's biotech ecosystem offers tax incentives and proximity to clinical sites, enhancing yield for DACH portfolios. VYVGART's approvals in gMG and CIDP across EU markets, including Germany, position argenx for localized revenue growth.

Switzerland's medtech hub and Austria's innovation grants could foster partnerships. Amid U.S. election uncertainties, argenx's global footprint diversifies risk. Biotech valuations remain attractive post-2025 corrections, with pipeline catalysts providing upside asymmetry.

The 61.9 million shares outstanding at year-end support liquidity for institutional flows from DACH funds.

Strategic Expansions into Rheumatology and Beyond

Pivotal data in autoimmune inflammatory myopathies (AIM/Myositis) and Sjögren’s disease (SjD) could redefine efgartigimod's scope. Combination strategies and next-gen FcRn blockers like ARGX-213 target long-term dominance. Empasiprubart's MMN readout sets a new standard in neuromuscular therapies, leveraging C2 inhibition's novel mechanism.

Pediatric extensions in gMG (ADAPT-JUNIOR IV/SC) address lifecycle management. Despite discontinuations in lupus nephritis and thyroid eye disease, the pipeline's breadth mitigates risks. Global partnerships, like with Zai Lab, enhance Asia reach.

These moves matter as immunology shifts toward precision mechanisms, with argenx leading FcRn and complement modulation.

Key Risks and Execution Challenges Ahead

Biotech pipelines carry inherent risks: trial failures, regulatory delays, or competitive entrants could pressure valuations. Heavy R&D spend strains cash flows, though $4.2B sales provide buffer. Patent cliffs loom post-2030, necessitating sustained innovation.

CEO transition introduces mild uncertainty, despite planning. Macro factors like inflation or reimbursement squeezes in Europe pose headwinds. Discontinued trials highlight selectivity needs, but overall success rates in late-stage assets remain promising.

DACH investors must weigh these against catalysts: balanced portfolios favor argenx's risk-reward profile in immunology.

Market Positioning and Long-Term Value Creation

Argenx's SIMPLE Antibody platform and IIP differentiate it, powering first-in-class assets. Commercial-stage status with VYVGART de-risks the model, unlike pure-play developers. Global approvals span U.S., Japan, Europe, Middle East, Africa, and China.

2026 outlook emphasizes 12-18 month catalysts, positioning for sustained growth. For investors, argenx exemplifies European biotech excellence, blending U.S. scale with EU agility.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.